<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753426</url>
  </required_header>
  <id_info>
    <org_study_id>15-17569</org_study_id>
    <nct_id>NCT02753426</nct_id>
  </id_info>
  <brief_title>A Trial of Doxycycline in Renal Disease</brief_title>
  <acronym>ADORE</acronym>
  <official_title>A Trial of Doxycycline in Renal Disease (ADORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this trial is to evaluate whether subantimicrobial-dose of doxycycline (20mgBID)
      will affect serum and urine biomarkers of fibrosis in patients with pre-dialysis chronic
      kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, placebo-controlled, randomized crossover trial to determine the effects of
      4-week treatment with subantimicrobial-dose doxycycline on serum and urine biomarkers of
      fibrosis in patients with pre-dialysis chronic kidney disease (eGFR&lt;30ml/min/1.73m2).
      Doxycycline is a matrix metalloproteinase inhibitor and is approved for use as an
      anti-fibrotic in the setting of gum and skin disease at low doses (20mgBID). At such a dose,
      serum levels are too low for antimicrobial effect and chronic usage is not thought to lead to
      tetracycline resistance. Investigators hypothesize that doxycycline will ameliorate cardiac
      and renal fibrosis and thus investigators will detect a decrease in fibrotic markers during
      treatment with doxycycline.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum markers of fibrosis</measure>
    <time_frame>3 months</time_frame>
    <description>Serum collagen type III amino-terminal propeptide (PIIINP), soluble suppression of tumorigenicity 2 (ST2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary markers of fibrosis</measure>
    <time_frame>3 months</time_frame>
    <description>Urinary PIIINP, Urinary alpha-1 macroglobulin (A1M)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>3 months</time_frame>
    <description>Nausea, rash</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cardiorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline 20mg capsule by mouth, twice a day for 30 days.</description>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Doxycycline)</intervention_name>
    <description>Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.</description>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD pre-dialysis (eGFR&lt; 30 ml/min/1.73m2 not on dialysis);

          -  local 415/650/510 area codes;

          -  primary language English or Spanish

        Exclusion Criteria:

          -  eGFR worsening by greater than 5ml/min/1.73 m2 during the last 6 months;

          -  Systolic blood pressure less than 100mmHg or greater than 170 mmHg;

          -  pregnancy;

          -  ejection fraction less than 45%;

          -  NYHA class III or IV HF;

          -  myocardial infarction or hospitalization for HF within 4 months;

          -  liver disease;

          -  moderate or severe chronic obstructive pulmonary disease or pulmonary fibrosis;

          -  current infection;

          -  chemotherapy;

          -  major surgery within last month;

          -  bilateral dialysis access precluding lab draw;

          -  self-reported use of IV drugs or cocaine within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Dubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

